Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.260
+0.050 (4.13%)
At close: Apr 28, 2026, 4:00 PM EDT
1.246
-0.014 (-1.11%)
Pre-market: Apr 29, 2026, 8:44 AM EDT

Dermata Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Selling, General & Admin
4.844.313.974.024.4
Upgrade
Research & Development
2.938.24.075.653.46
Upgrade
Operating Expenses
7.7712.518.049.677.86
Upgrade
Operating Income
-7.77-12.51-8.04-9.67-7.86
Upgrade
Interest Expense
-----0.05
Upgrade
Interest & Investment Income
0.220.230.250.06-
Upgrade
EBT Excluding Unusual Items
-7.56-12.29-7.79-9.61-7.9
Upgrade
Pretax Income
-7.56-12.29-7.79-9.61-7.9
Upgrade
Net Income
-7.56-12.29-7.79-9.61-7.9
Upgrade
Preferred Dividends & Other Adjustments
----2.56
Upgrade
Net Income to Common
-7.56-12.29-7.79-9.61-10.46
Upgrade
Shares Outstanding (Basic)
100--
Upgrade
Shares Outstanding (Diluted)
100--
Upgrade
Shares Change (YoY)
505.46%684.76%---
Upgrade
EPS (Basic)
-8.16-80.32-399.87--
Upgrade
EPS (Diluted)
-8.16-80.32-399.87--
Upgrade
EBITDA
-----7.86
Upgrade
D&A For EBITDA
----0
Upgrade
EBIT
-7.77-12.51-8.04-9.67-7.86
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.